1 completed, 1 terminated, 1 unknown, 1 withdrawn. 2 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 4 | 2 | Unknown 1, Withdrawn 1 |
Follow Pedro Cahn: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study Dolutegravir plus lamivudine - HIV-1 Infection | Phase 4 | Withdrawn | Pedro Cahn | 2019-05-22 | 2022-04-12 | |
| RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients Ritonavir boosted Atazanavir, Raltegravir, TDF/FTC (or 3TC) - Chronic Infection With HIV | Phase 4 | Unknown | Pedro Cahn | 50 | 2014-05-01 | 2017-01-24 |
| Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects. lopinavir/ritonavir plus one nucleoside, lopinavir /ritonavir plus two nucleosides - HIV Infection | Phase 3 | Completed | Pedro Cahn | 417 | 2010-12-01 | 2012-06-12 |
| Raltegravir Added to Stable HAART in HIV-1 Infected Subjects With Viral Suppression and Low CD4 Recovery Raltegravir, Placebo - HIV Infections | Phase 3 | Terminated | Pedro Cahn | 20 | 2008-08-01 | 2015-06-09 |
HIV Infections (2)
Raltegravir Potassium (2) · Ritonavir (2) · Atazanavir Sulfate (1) · Dual Anti-Platelet Therapy (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Lamivudine (1) · Lopinavir (1) · dolutegravir (1)
Argentina (4)